Lantis, Andrea C.;
Atkins, Clarke E.;
DeFrancesco, Teresa C.;
Keene, Bruce W.;
Werre, Stephen R.
Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs
Contributor:
Lantis, Andrea C.;
Atkins, Clarke E.;
DeFrancesco, Teresa C.;
Keene, Bruce W.;
Werre, Stephen R.
imprint:
American Veterinary Medical Association (AVMA), 2011
Published in:American Journal of Veterinary Research
Description:
<jats:title>Abstract</jats:title>
<jats:p><jats:bold>Objective</jats:bold>—To evaluate the effect of administration of the labeled dosage of pimobendan to dogs with furosemide-induced activation of the renin-angiotensin-aldosterone system (RAAS).</jats:p>
<jats:p><jats:bold>Animals</jats:bold>—12 healthy hound-type dogs.</jats:p>
<jats:p><jats:bold>Procedures</jats:bold>—Dogs were allocated into 2 groups (6 dogs/group). One group received furosemide (2 mg/kg, PO, q 12 h) for 10 days (days 1 to 10). The second group received a combination of furosemide (2 mg/kg, PO, q 12 h) and pimobendan (0.25 mg/kg, PO, q 12 h) for 10 days (days 1 to 10). To determine the effect of the medications on the RAAS, 2 urine samples/d were obtained for determination of the urinary aldosterone-to-creatinine ratio (A:C) on days 0 (baseline), 5, and 10.</jats:p>
<jats:p><jats:bold>Results</jats:bold>—Mean ± SD urinary A:C increased significantly after administration of furosemide (baseline, 0.37 ± 0.14 μg/g; day 5, 0.89 ± 0.23 μg/g) or the combination of furosemide and pimobendan (baseline, 0.36 ± 0.22 μg/g; day 5, 0.88 ± 0.55 μg/g). Mean urinary A:C on day 10 was 0.95 ± 0.63 μg/g for furosemide alone and 0.85 ± 0.21 μg/g for the combination of furosemide and pimobendan.</jats:p>
<jats:p><jats:bold>Conclusions and Clinical Relevance</jats:bold>—Furosemide-induced RAAS activation appeared to plateau by day 5. Administration of pimobendan at a standard dosage did not enhance or suppress furosemide-induced RAAS activation. These results in clinically normal dogs suggested that furosemide, administered with or without pimobendan, should be accompanied by RAAS-suppressive treatment.</jats:p>